Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.67 |
| ▸ | KCNN3 | Q9UGI6 | 14/20 | 0.49 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.49 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | LTK | P29376 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869 | 0.80 | PDE10A (1.00) | PDE10AKCNN3KCNN1KCNN2CHEK1 | |
| SCHEMBL17026690 | 0.80 | CDK2 (0.48) | PDE10AKCNN3KCNN1KCNN2CHEK1 | |
| SCHEMBL29344715 | 0.77 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL14316241 | 0.77 | CDK2 (0.46) | PDE10AKCNN3KCNN1KCNN2CHEK1 | |
| SCHEMBL1290450 | 0.77 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2CHEK1 | |
| SCHEMBL4431791 | 0.77 | ALDH1A1 (0.50) | PDE10ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7885210 | 0.77 | PDE10A (0.43) | PDE10AKCNN3KCNN1KCNN2CHEK1 | |
| SCHEMBL7845288 | 0.76 | KDM4E (0.48) | PDE10ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7846659 | 0.74 | HSP90AA1 (0.49) | PDE10AKCNN3KCNN1KCNN2CHEK1 | |
| SCHEMBL1018372 | 0.73 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109475-A1 | SHP-1 AGONISTS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-114634432-B | High-efficiency synthesis method of alkyl aryl thioether compound | 润药仁智(北京)科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-114634432-A | High-efficiency synthesis method of alkyl aryl thioether compound | 北京大学 | 2022-06-17 | — | — | CN | disclosed |
| EP-2736338-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-2736338-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2621925-B1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2621925-B1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | PDE10A 1523/4885KCNN3 3579/4885KCNN1 3684/4885 |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | JUN, CHUK, RELA | PDE10A 2997/4885KCNN3 3885/4885KCNN1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.